Physician profile
John David Mandeville
NPI 1306017959
$3,266.79
in general payments reported to CMS, 2019-2025
40 companies · $526 in 2025
The $526 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $836 · 2020: $500 · 2021: $98.31 · 2022: $302 · 2023: $465 · 2024: $540 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,515 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,515.30 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $607.41 | 2019-2025 | Apretude |
| Gilead Sciences, INC. | $495.70 | 2019-2024 | Biktarvy |
| Abbvie INC. | $240.34 | 2019-2025 | |
| Novo Nordisk INC | $236.63 | 2021-2025 | Wegovy |
| Amgen INC. | $220.04 | 2019-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $211.65 | 2019-2025 | Shingrix, Arexvy, Pediarix |
| Pfizer INC. | $194.03 | 2019-2025 | |
| Lilly USA, LLC | $138.30 | 2021-2025 | Zepbound, Mounjaro |
| Exact Sciences Corporation | $101.04 | 2024-2025 | Cologuard Collection Kit |
| Neurocrine Biosciences, INC. | $78.62 | 2024-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.00 | 2023-2024 | Caplyta |
| Xeris Pharmaceuticals, INC. | $46.54 | 2025 | Keveyis |
| Janssen Biotech, INC. | $39.53 | 2019-2020 | |
| Organon LLC | $37.39 | 2024 | |
| Alkermes, INC. | $36.24 | 2024 | Vivitrol |
Show all 39 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mandeville listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.